% | $
Quotes you view appear here for quick access.

Omeros Corporation Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • tredleon tredleon Dec 29, 2012 9:57 AM Flag

    Buy ratings and new price targets on Friday

    Dooper - Minyanville also reported that Burrill reiterated an Outperform, but took the price target down from $19 to $16. Not that the market is paying attention, but it is good to see some legitimate analysts with targets 2.5-3X the current price. While I believe the company has a rational position to move from the KOOS endpoint to the pain/inflammation endpoint for the second OMS103 trial, it will be a cloud over the clinical path for OMS103 for some time - i.e. even if the second trial is successful in having a very robust p-value on the pain/inflammation endpoint, there will still be skepticism on whether the FDA will accept this shift in primary endpoints - so, the potential value of the OMS103 program will not be reflected in the stock price until 2014 at the earliest. At this point, the question becomes will they partner OMS302 (or some other program) in order to avoid dilution until they get OMS302 approved and start generating revenue? Any guesses?

    SortNewest  |  Oldest  |  Most Replied Expand all replies
11.42+0.12(+1.06%)May 27 4:00 PMEDT